The most intensely investigated targets for drug delivery to high-grade gliomas are vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR), including the truncated, constitutively active variant EGFRvIII [67,106,255,256]. The gene discussed is VEGFA; the disease is glioma.